Dr. Lal Path Labs Ltd. — PPTs, 30-01-2026: Investor Presentation

Here's a concise, retail-friendly summary:

**1. Business Performance:** Q3 FY26 revenue reached Rs. 660 Cr (+10.6% YoY), with 9M FY26 at Rs. 2,060 Cr (+10.8%). Q3 PAT was Rs. 91 Cr, impacted by a labor code charge; 9M PAT grew 12.2% to Rs. 378 Cr. Patient volumes rose 7.8% in Q3, driven by city expansion and SwasthFit contributing 26% to YTD revenue.

**2. Growth Drivers or Strategy:** Strategies include leveraging digital infrastructure (AI/ML for efficiency), expanding networks in West & South India, and enhancing super-specialty and bundled test portfolios.

**3. Recent Developments:** Over 15 new advanced tests (some "First in India") and the "Sovaaka" preventive wellness program were launched. IT upgrades and new digital tools improve patient/clinician experience, accelerating reporting.

**4. Key Financial Metrics:** Q3 FY26 EBITDA (pre-exceptional) grew 16.3% YoY to Rs. 179 Cr (27.2% margin). 9M FY26 Basic EPS was Rs. 22.4 (+12.2% YoY).

**5. Management Commentary / Outlook:** Management expects sustained organic growth, healthy profitability, and efficient cost control. They aim to leverage technology and network expansion to capture India's organized diagnostics market, targeting consistent, high-quality earnings.